ImmunoPrecise Antibodies Ltd. (IPA): Earnings growth forecast for next year
The business resilience of ImmunoPrecise Antibodies (IPA) is based on the implementation of autonomous microfluidic systems for B-cell screening. The trend in market expectations for EPS growth clearly confirms this potential, where the value of 139.50 corresponds to the current metric. ImmunoPrecise Antibodies (IPA) generates revenue through R&D outsourcing for the biotech sector, while its expansion relies on the BioStrand AI platform and the monetization of unique antibody libraries.
Metric breakdowns and analytics for ImmunoPrecise Antibodies Ltd. (IPA)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- company liabilities and liquidity data:
Total Debt to Capital ImmunoPrecise Antibodies|IPA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio ImmunoPrecise Antibodies Ltd|IPA - Aggregate Debt Obligations|Debts to Book Capitalization ImmunoPrecise Antibodies|IPA - Company Long-Term Debts|Company Short-Term Debt ImmunoPrecise Antibodies|Quick Liquidity Indicator immunoprecise.com
- earnings and valuation multiples information:
IPA - Profit After Payment of Taxes|Projected Future Earnings ImmunoPrecise Antibodies|IPA - Business Payback Period|Forward P/E Multiple ImmunoPrecise Antibodies Ltd|IPA - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ImmunoPrecise Antibodies|IPA - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) ImmunoPrecise Antibodies|IPA - Earnings per share for the last 12 months|Quarterly EPS earnings growth immunoprecise.com|IPA - Expected net earnings per share growth this year|Earnings growth forecast for next year ImmunoPrecise Antibodies
Fundamental company valuation:ImmunoPrecise Antibodies, IPA
ImmunoPrecise Antibodies (IPA) monetizes its LENS ai AI system by reducing Big Pharma's antibody discovery costs. This indicator tracks analyst consensus expectations for next year's profit growth rates, allowing investors to identify hidden overvaluation or undervalued assets through the dynamics of next year's consensus EPS forecasts during earnings reporting periods.
Main competitors
TEM (Tempus AI, Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Qiagen Corp QGEN|Earnings growth forecast for next year IONS|Expected earnings per share growth for next year repligen.com RGEN|Earnings growth forecast for next year RNA (Avidity Biosciences, Inc.)|Consensus forecast of earnings per share growth for next year CRISPR Therapeutics Inc (CRSP)|WGS - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year Ultragenyx Corp RARE|BEAM: Earnings growth forecast for next year|Expected net earnings per share growth next year sarepta.com (SRPT)|Expected earnings per share growth for next year TWST|TXG: Expected earnings per share trend next year|Earnings growth forecast for next year NTLA|Earnings growth forecast for next year Stoke Corp (STOK)|Net earnings per share growth forecast for next year BioLife Solutions, Inc. BLFS|WVE: Projected earnings per share growth rate for next year|MAZE: Expected earnings per share growth for next year|Sionna Therapeutics, Inc. - Projected earnings per share increase next year|PRME: Earnings growth forecast for next year|TSHA - Consensus forecast of earnings per share growth for next year|QURE (uniQure N.V.) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year MGTX|Net earnings per share growth forecast for next year REGENXBIO (RGNX)|SLDB - Expected net earnings per share growth next year|Earnings growth forecast for next year OCGN (Ocugen Corp)|PACB: Projected earnings per share growth rate for next year|Benitec Biopharma Inc. - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year designtx.com DSGN|RCKT: Earnings growth forecast for next year|Expected net earnings per share growth next year 4DMT (FDMT)|Net earnings per share growth forecast for next year Lexeo Therapeutics Inc.|Korro Bio, Inc (KRRO) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year EDIT|Consensus forecast of earnings per share growth for next year silence-therapeutics.com|Net earnings per share growth forecast for next year ProQR Therapeutics PRQR|CDXS (Codexis Inc) - Net earnings per share change forecast for next year|Sangamo - Earnings growth forecast for next year|NAUT - Earnings growth forecast for next year|MGX: Earnings growth forecast for next year|Projected earnings per share growth rate for next year DTIL|Net earnings per share growth forecast for next year Generation Bio Co|Projected earnings per share growth rate for next year BOLD (Boundless Bio Inc.)|Earnings growth forecast for next year XCUR|Earnings growth forecast for next year imunon.com (IMNN)|Earnings growth forecast for next year PHIO (Phio Pharmaceuticals Corp.)|Consensus forecast of earnings per share growth for next year Mustang Bio Inc (MBIO)|RNAZ - Net earnings per share growth forecast for next year|Bionano Genomics, Inc. (BNGO) - Expected earnings per share growth for next year|Applied DNA (APDN) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year bluebird bio, Inc|Expected earnings per share growth for next year OMGA|Earnings growth forecast for next year singulargenomics.com|Net earnings per share growth forecast for next year Regulus Therapeutics Inc. (RGLS)|Syros Pharmaceuticals Inc. - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year Codex DNA TBIO|TRACON Pharmaceuticals, Inc (TCON) - Expected net earnings per share growth next year|UBX - Net earnings per share growth forecast for next year
